AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8346957 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine 5 micrograms/kg/min, increased to 20 micrograms/kg/min if needed
Number of subjects: 20
Study 8346957 — intervention group
Group type: EXPERIMENTAL
Intervention: dopamine 5 micrograms/kg/min, increased to 12.5 micrograms/kg/min if needed
Number of subjects: 20
Study 8346957 — intervention group
Group type: EXPERIMENTAL
Intervention: switch from dobutamine to dopamine
Number of subjects: 20
Study 3730530 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of diethylamine chromocarbe 0.5 h before breakfast
Number of subjects: 8
Study 3730530 — intervention group
Group type: COMPARATOR
Intervention: Administration of diethylamine chromocarbe at lunch
Number of subjects: 8
Study 3730530 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of diethylamine chromocarbe before dinner
Number of subjects: 8
Study 31377034 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC-DRS 3
Number of subjects: 1769
Study 31377034 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-RADS 4B
Number of subjects: 1769
Study 29716702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (titrated to maximum 7.5mg BD)
Number of subjects: 187
Study 29716702 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (beta blockers, ACEI, diuretics)
Number of subjects: 187
Study 27834812 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with weekly motivational encouragement through text messages and access to a study website
Number of subjects: 28
Study 27834812 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 27834812 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIIT without motivational support)
Number of subjects: 28
Study 24162260 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously monthly
Number of subjects: 1597
Study 24162260 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously monthly
Number of subjects: 1597
Study 22493422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg/d for 16 weeks
Number of subjects: 272
Study 22493422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib (double-blind)
Number of subjects: 272
Study 22493422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 272
Study 22493422 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 272
Study 22493422 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 272
Study 20461090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenous weekly)
Number of subjects: 0
Study 20461090 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (titrated to 18 mU three times weekly)
Number of subjects: 0
Study 20461090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (15 mg intravenous weekly) plus interferon-alpha (6 mU three times weekly)
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacereine
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado/soybean unsaponifiables
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitonin
Number of subjects: 0
Study 19087296 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 15960408 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 ProSeal laryngeal mask airway (PLMA) in male patients
Number of subjects: 60
Study 15960408 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 4 ProSeal laryngeal mask airway (PLMA) in female patients
Number of subjects: 60
Study 15960408 — intervention group
Group type: COMPARATOR
Intervention: Size 3 ProSeal laryngeal mask airway (PLMA) in female patients
Number of subjects: 60
Study 12610009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% alcohol beer
Number of subjects: 16
Study 12610009 — intervention group
Group type: COMPARATOR
Intervention: Usual alcohol intake
Number of subjects: 16
Study 10700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 216
Study 8607670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 g before incision)
Number of subjects: 210
Study 8607670 — intervention group
Group type: COMPARATOR
Intervention: Control (250 mL placebo saline solution)
Number of subjects: 210
Study 2016229 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30
Study 2016229 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 30
Study 2016229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7128130 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 2970
Study 7128130 — intervention group
Group type: COMPARATOR
Intervention: Lippes Loop D
Number of subjects: 2970
Study 7128130 — intervention group
Group type: COMPARATOR
Intervention: Copper 7
Number of subjects: 2970
Study 30507731 — intervention group
Group type: EXPERIMENTAL
Intervention: With Personal Protective Equipment (WPPE, load = 12.0 kg)
Number of subjects: 13
Study 30507731 — intervention group
Group type: COMPARATOR
Intervention: Without Personal Protective Equipment (NPPE, load = 5.2 kg)
Number of subjects: 13
Study 30507731 — intervention group
Group type: EXPERIMENTAL
Intervention: With Personal Protective Equipment (WPPE)
Number of subjects: 13
Study 31030882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden gains
Number of subjects: 44
Study 31030882 — intervention group
Group type: COMPARATOR
Intervention: Gradual gains
Number of subjects: 44
Study 28231831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 59
Study 28231831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 27821162 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 6
Study 27821162 — intervention group
Group type: COMPARATOR
Intervention: CV
Number of subjects: 6
Study 23817922 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of the action sequence
Number of subjects: 0
Study 23817922 — intervention group
Group type: COMPARATOR
Intervention: Spoken repetition of instructions
Number of subjects: 0
Study 23072844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine hydrochloride without adrenaline (xylocaine 2%) - 2 mL
Number of subjects: 50
Study 23072844 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine hydrochloride with adrenaline 1:80,000 - 2 mL
Number of subjects: 50
Study 19588529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,440‐nm Nd:YAG fractional laser (average fluence 3.7+/‐0.3 J/cm(2))
Number of subjects: 19
Study 19588529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,320/1,440‐nm multiplex Nd:YAG fractional laser (1,320‐nm average fluence 8.4+/‐0.4 J/cm(2); 1,440‐nm average fluence 2.3+/‐0.2 J/cm(2))
Number of subjects: 19
Study 19588529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 19
Study 17969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyin Oral Liquid (SOL)
Number of subjects: 117
Study 17969889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17969889 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 117
Study 14985689 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA meal (40 g MUFA; 12 g SFA)
Number of subjects: 19
Study 14985689 — intervention group
Group type: COMPARATOR
Intervention: SFA meal (20 g MUFA; 32 g SFA)
Number of subjects: 19
Study 14985689 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA meal
Number of subjects: 19
Study 14985689 — intervention group
Group type: COMPARATOR
Intervention: SFA meal
Number of subjects: 19
Study 11440963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz given daily at 125 mg p.o.
Number of subjects: 201
Study 11440963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz given once per week at 500 mg p.o.
Number of subjects: 201
Study 11440963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 11440963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 201
Study 11440963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 201
Study 9730996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microgram twice daily)
Number of subjects: 24
Study 9730996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8055363 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium (EHDP)
Number of subjects: 0
Study 8055363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2659234 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study 2659234 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 10
Study 2659234 — intervention group
Group type: COMPARATOR
Intervention: Adenosine infusion
Number of subjects: 10
Study 4733248 — intervention group
Group type: EXPERIMENTAL
Intervention: Different periods of fasting
Number of subjects: 33
Study 4733248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood sugar
Number of subjects: 33
Study 31089014 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sugammadex 2 mg.kg‐1
Number of subjects: 66
Study 31089014 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.04 mg.kg‐1 + atropine 0.01 mg.kg‐1
Number of subjects: 66
Study 28245537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic lithotripter (Swiss LithoClast® Master)
Number of subjects: 29
Study 28245537 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic lithotripter (Swiss LithoClast®)
Number of subjects: 29
Study 26159135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile web-based pregnancy health care educational program for 2 weeks
Number of subjects: 61
Study 26159135 — intervention group
Group type: COMPARATOR
Intervention: Classroom education booklet for pregnant women
Number of subjects: 61
Study 23021205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention combined with daily low-glycaemic index meal replacement
Number of subjects: 88
Study 23021205 — intervention group
Group type: COMPARATOR
Intervention: Control group (health counselling only)
Number of subjects: 88
Study 21510886 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Number of subjects: 401
Study 21510886 — intervention group
Group type: COMPARATOR
Intervention: Traditional care in an orthopaedic ward
Number of subjects: 401
Study 18291049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dräger Evita XL
Number of subjects: 21
Study 18291049 — intervention group
Group type: EXPERIMENTAL
Intervention: Maquet Servo‐i
Number of subjects: 21
Study 18291049 — intervention group
Group type: EXPERIMENTAL
Intervention: Newport e500
Number of subjects: 21
Study 18291049 — intervention group
Group type: EXPERIMENTAL
Intervention: Puritan Bennett 840
Number of subjects: 21
Study 18291049 — intervention group
Group type: COMPARATOR
Intervention: All ventilators
Number of subjects: 21
Study 16933235 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-Ab(XTL)68 120 mg
Number of subjects: 24
Study 16933235 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-Ab(XTL)68 240 mg
Number of subjects: 24
Study 16933235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16933235 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments combined
Number of subjects: 24
Study 15309392 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (initial dose of 20mg, with increments to a maximum of 60 mg over 8 weeks)
Number of subjects: 39
Study 15309392 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 39
Study 15309392 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 39
Study 11401871 — intervention group
Group type: EXPERIMENTAL
Intervention: PC(20) adenosine 5'-monophosphate (AMP)
Number of subjects: 120
Study 11401871 — intervention group
Group type: COMPARATOR
Intervention: PC(20) methacholine
Number of subjects: 120
Study 9406266 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose olanzapine (5 to 15 mg a day)
Number of subjects: 120
Study 9406266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9406266 — intervention group
Group type: COMPARATOR
Intervention: Ineffective-dose olanzapine (1 mg a day)
Number of subjects: 120
Study 8221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (participated in the sexual abuse prevention program)
Number of subjects: 117
Study 8221219 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 117
Study 8221219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest authority scores
Number of subjects: 117
Study 3312603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 27
Study 3312603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30199288 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in CACFP
Number of subjects: 680
Study 30199288 — intervention group
Group type: EXPERIMENTAL
Intervention: Child care centers
Number of subjects: 680
Study 30199288 — intervention group
Group type: EXPERIMENTAL
Intervention: New CACFP standards
Number of subjects: 680
Study 30199288 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of introduction of solids, serving sweet grains, serving yogurt low in sugar, serving appropriate milk types
Number of subjects: 680
Study 28253050 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking plus exclusion feedback
Number of subjects: 96
Study 28253050 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking plus neutral feedback
Number of subjects: 96
Study 28253050 — intervention group
Group type: COMPARATOR
Intervention: Sedentary plus exclusion feedback
Number of subjects: 96
Study 28253050 — intervention group
Group type: COMPARATOR
Intervention: Sedentary plus neutral feedback
Number of subjects: 96
Study 28253050 — intervention group
Group type: COMPARATOR
Intervention: Sedentary prior to exclusion
Number of subjects: 96
Study 28253050 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 96
Study 26198433 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional Medication Therapy Management (MTM) approach
Number of subjects: 165
Study 23916488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 501
Study 23916488 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.50 mg)
Number of subjects: 501
Study 20233526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningdong (ND) granule, 1 g/kg per day, n = 33
Number of subjects: 64
Study 20233526 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 31
Number of subjects: 64
Study 18550156 — intervention group
Group type: EXPERIMENTAL
Intervention: HT008-1
Number of subjects: 118
Study 18550156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16809911 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg x min)
Number of subjects: 17
Study 16809911 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 17
Study 12672313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched diet
Number of subjects: 216
Study 12672313 — intervention group
Group type: COMPARATOR
Intervention: Lower-nutrient diet
Number of subjects: 216
Study 12672313 — intervention group
Group type: COMPARATOR
Intervention: Reference group (born at term)
Number of subjects: 216
Study 10664518 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone (group 1, n=44)
Number of subjects: 135
Study 10664518 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole + T3 (group 2, n=39)
Number of subjects: 135
Study 10664518 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 alone (group 3, n=31)
Number of subjects: 135
Study 8872973 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI withdrawal (enalapril or captopril replaced by nifedipine or clonidine)
Number of subjects: 15
Study 8872973 — intervention group
Group type: COMPARATOR
Intervention: ACEI (enalapril or captopril)
Number of subjects: 15
Study 1524606 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 60
Study 1524606 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 60
Study 6479685 — intervention group
Group type: EXPERIMENTAL
Intervention: Celestin technique
Number of subjects: 72
Study 6479685 — intervention group
Group type: COMPARATOR
Intervention: Eder-Puestow technique
Number of subjects: 72
Study 30626287 — intervention group
Group type: EXPERIMENTAL
Intervention: 4×40 stent retriever
Number of subjects: 715
Study 30626287 — intervention group
Group type: COMPARATOR
Intervention: 4×20 stent retriever
Number of subjects: 715
Study 30626287 — intervention group
Group type: COMPARATOR
Intervention: 6×30 stent retriever
Number of subjects: 715
Study 30626287 — intervention group
Group type: EXPERIMENTAL
Intervention: All stent retriever sizes
Number of subjects: 715
Study 30185111 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 52
Study 30185111 — intervention group
Group type: COMPARATOR
Intervention: Random practice
Number of subjects: 52
Study 30185111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both practice groups
Number of subjects: 52
Study 27174641 — intervention group
Group type: EXPERIMENTAL
Intervention: Family partnership intervention (FPI)
Number of subjects: 117
Study 27174641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and family education (PFE)
Number of subjects: 117
Study 27174641 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 117
Study 25078900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300 (insulin glargine 300 units/mL)
Number of subjects: 807
Study 25078900 — intervention group
Group type: COMPARATOR
Intervention: Gla‐100 (insulin glargine 100 units/mL)
Number of subjects: 807
Study 21807480 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-Omega3
Number of subjects: 200
Study 21807480 — intervention group
Group type: COMPARATOR
Intervention: PS-Omega3 (after switching from placebo)
Number of subjects: 200
Study 20106943 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA) therapy
Number of subjects: 232
Study 17555412 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettes (H-group)
Number of subjects: 72
Study 17555412 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (L-group)
Number of subjects: 72
Study 17555412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic device (S-group)
Number of subjects: 72
Study 17555412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (U-group)
Number of subjects: 72
Study 17555412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic treatment
Number of subjects: 72
Study 16298722 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+EX
Number of subjects: 217
Study 16298722 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 217
Study 12224568 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasight-F test
Number of subjects: 143
Study 10193874 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and carbohydrate diet (HP/C)
Number of subjects: 8
Study 10193874 — intervention group
Group type: COMPARATOR
Intervention: High fat diet (HF)
Number of subjects: 8
Study 8851647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 8851647 — intervention group
Group type: COMPARATOR
Intervention: Standard neuroleptic therapy
Number of subjects: 0
Study 2076683 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 300
Study 2076683 — intervention group
Group type: COMPARATOR
Intervention: Sharp curettage (control)
Number of subjects: 300
Study 375147 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 317
Study 375147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 317
Study 375147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 375147 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hysterectomy (Penicillin or Cefazolin)
Number of subjects: 317
Study 375147 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 317
Study 31033232 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based outpatient physical therapy (PT) intervention (6 sessions)
Number of subjects: 180
Study 31033232 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 30871514 — intervention group
Group type: EXPERIMENTAL
Intervention: Green cardamom (GC) supplementation, 500 mg capsules, 3 times/day for 3 months
Number of subjects: 87
Study 30871514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 28986058 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill group
Number of subjects: 3140
Study 26404640 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) intervention group, n=655
Number of subjects: 1341
Study 26404640 — intervention group
Group type: COMPARATOR
Intervention: Control group (school as usual), n=735
Number of subjects: 1341
Study 22907065 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized thoracolumbosacral orthosis (TLSO)
Number of subjects: 23
Study 22907065 — intervention group
Group type: COMPARATOR
Intervention: No-brace
Number of subjects: 23
Study 23084675 — intervention group
Group type: EXPERIMENTAL
Intervention: LUAL + ISM
Number of subjects: 144
Study 23084675 — intervention group
Group type: COMPARATOR
Intervention: ISM
Number of subjects: 144
Study 19934131 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features (age, duration of symptoms, sex, radiation of pain to the right arm)
Number of subjects: 1576